Hepatitis Monthly

Published by: Kowsar

Enhancement of Immune Responses by Co-delivery of CCL19/MIP-3beta Chemokine Plasmid With HCV Core DNA/Protein Immunization

Christine Hartoonian 1 , 2 , Zargham Sepehrizadeh 1 , * , Mojtaba Tabatabai Yazdi 1 , Yong Suk Jang 3 , Lida Langroudi 2 , Parisa Amir Kalvanagh 2 , 4 , Babak Negahdari 4 , 5 , Ali Karami 6 , Massoumeh Ebtekar 4 and Kayhan Azadmanesh 2 , *
Authors Information
1 Department of Pharmaceutical Biotechnology and Biotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, IR Iran
2 Department of Virology, Pasteur Institute of Iran, Tehran, IR Iran
3 Departments of Molecular Biology and Bioactive Material Sciences, Institute for Molecular Biology and Genetics, Chonbuk National University, Jeonju, Korea
4 Department of Immunology, Faculty of Medical Sciences, Tarbiat Modaress University, Tehran, IR Iran
5 Department of Medical Biotechnology, School of Advanced Technologies, Tehran University of Medical Sciences, Tehran, IR Iran
6 Department of Research Center of Molecular Biology, Baqyiatallah University of Medical Sciences, Tehran, IR Iran
Corresponding Authors:
Article information
  • Hepatitis Monthly: March 2014, 14 (3); e14611
  • Published Online: March 1, 2014
  • Article Type: Research Article
  • Received: September 22, 2013
  • Revised: December 1, 2013
  • Accepted: December 5, 2013
  • DOI: 10.5812/hepatmon.14611

To Cite: Hartoonian C, Sepehrizadeh Z, Tabatabai Yazdi M, Jang Y S, Langroudi L, et al. Enhancement of Immune Responses by Co-delivery of CCL19/MIP-3beta Chemokine Plasmid With HCV Core DNA/Protein Immunization, Hepat Mon. 2014 ;14(3):e14611. doi: 10.5812/hepatmon.14611.

Copyright: Copyright © 2014, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
  • 1. Kim CW, Chang KM. Hepatitis C virus: virology and life cycle. Clin Mol Hepatol. 2013; 19(1): 17-25
  • 2. Pavio N, Lai MM. The hepatitis C virus persistence: how to evade the immune system? J Biosci. 2003; 28(3): 287-304[PubMed]
  • 3. Gellad ZF, Reed SD, Muir AJ. Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C. Antivir Ther. 2012; 17(6 Pt B): 1189-99[DOI][PubMed]
  • 4. Esteban R, Buti M. Triple therapy with boceprevir or telaprevir for treatment naive HCV patients. Best Pract Res Clin Gastroenterol. 2012; 26(4): 445-53[DOI][PubMed]
  • 5. Kozielewicz D, Halota W, Dybowska D. [Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively]. Przegl Epidemiol. 2012; 66(1): 49-54[PubMed]
  • 6. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000; 132(4): 296-305[PubMed]
  • 7. Liao G, Wang Y, Chang J, Bian T, Tan W, Sun M, et al. Hepatitis B virus precore protein augments genetic immunizations of the truncated hepatitis C virus core in BALB/c mice. Hepatology. 2008; 47(1): 25-34[DOI][PubMed]
  • 8. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989; 244(4902): 359-62[PubMed]
  • 9. Lowe DB, Shearer MH, Kennedy RC. DNA vaccines: successes and limitations in cancer and infectious disease. J Cell Biochem. 2006; 98(2): 235-42[DOI][PubMed]
  • 10. Barouch DH, Letvin NL, Seder RA. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev. 2004; 202: 266-74[DOI][PubMed]
  • 11. Tsen SW, Paik AH, Hung CF, Wu TC. Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines. 2007; 6(2): 227-39[DOI][PubMed]
  • 12. Ngo VN, Tang HL, Cyster JG. Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells. J Exp Med. 1998; 188(1): 181-91[PubMed]
  • 13. Forster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. Nat Rev Immunol. 2008; 8(5): 362-71[DOI][PubMed]
  • 14. Riol-Blanco L, Sanchez-Sanchez N, Torres A, Tejedor A, Narumiya S, Corbi AL, et al. The chemokine receptor CCR7 activates in dendritic cells two signaling modules that independently regulate chemotaxis and migratory speed. J Immunol. 2005; 174(7): 4070-80[PubMed]
  • 15. Kaiser A, Donnadieu E, Abastado JP, Trautmann A, Nardin A. CC chemokine ligand 19 secreted by mature dendritic cells increases naive T cell scanning behavior and their response to rare cognate antigen. J Immunol. 2005; 175(4): 2349-56[PubMed]
  • 16. Westermann J, Nguyen-Hoai T, Baldenhofer G, Hopken UE, Lipp M, Dorken B, et al. CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity. Cancer Gene Ther. 2007; 14(6): 523-32[DOI][PubMed]
  • 17. Eo SK, Lee S, Kumaraguru U, Rouse BT. Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands. Vaccine. 2001; 19(32): 4685-93[PubMed]
  • 18. Han YW, Aleyas AG, George JA, Kim SJ, Kim HK, Yoo DJ, et al. Genetic co-transfer of CCR7 ligands enhances immunity and prolongs survival against virulent challenge of pseudorabies virus. Immunol Cell Biol. 2009; 87(1): 91-9[DOI][PubMed]
  • 19. Juarez V, Pasolli HA, Hellwig A, Garbi N, Arregui AC. Virus-Like Particles Harboring CCL19, IL-2 and HPV16 E7 Elicit Protective T Cell Responses in HLA-A2 Transgenic Mice. Open Virol J. 2012; 6: 270-6[DOI][PubMed]
  • 20. Hartoonian C, Ebtekar M, Soleimanjahi H, Karami A, Mahdavi M, Rastgoo N, et al. Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine. Cytokine. 2009; 46(1): 43-50[DOI][PubMed]
  • 21. Yang J, Wang S, Zhao G, Sun B. Effect of chemokine receptors CCR7 on disseminated behavior of human T cell lymphoma: clinical and experimental study. J Exp Clin Cancer Res. 2011; 30: 51[DOI][PubMed]
  • 22. Roohvand F, Aghasadeghi MR, Sadat SM, Budkowska A, Khabiri AR. HCV core protein immunization with Montanide/CpG elicits strong Th1/Th2 and long-lived CTL responses. Biochem Biophys Res Commun. 2007; 354(3): 641-9[DOI][PubMed]
  • 23. Lohr HF, Schmitz D, Arenz M, Weyer S, Gerken G, Meyer zum Buschenfelde KH. The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies. J Hepatol. 1999; 31(3): 407-15[PubMed]
  • 24. Hartoonian C, Ebtekar M, Soleimanjahi H, Karami A, Mahdavi M, Rastgoo N, et al. Effect of immunological adjuvants: GM-CSF (granulocyte-monocyte colony stimulating factor) and IL-23 (interleukin-23) on immune responses generated against hepatitis C virus core DNA vaccine. Cytokine. 2009; 46(1): 43-50
  • 25. Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, Part one: Advances in basic knowledge for hepatitis C virus vaccine design. Expert Opin Ther Pat. 2011; 21(12): 1811-30[DOI][PubMed]
  • 26. Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities. Expert Opin Ther Pat. 2012; 22(4): 391-415[DOI][PubMed]
  • 27. Mohit E, Rafati S. Chemokine-based immunotherapy: delivery systems and combination therapies. Immunotherapy. 2012; 4(8): 807-40[DOI][PubMed]
  • 28. Hu K, Luo S, Tong L, Huang X, Jin W, Huang W, et al. CCL19 and CCL28 Augment Mucosal and Systemic Immune Responses to HIV-1 gp140 by Mobilizing Responsive Immunocytes into Secondary Lymph Nodes and Mucosal Tissue. J Immunol. 2013; 191(4): 1935-47[DOI][PubMed]
  • 29. Foged C. Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems. Ther Deliv. 2011; 2(8): 1057-77
  • 30. Yazdanian MMA, Mahdavi M, Sadat M, Motevali F, Vahabpour R, Khanhmad H, Siadat SD, Aghasadeghi MR, Roohvand F. Immunization of Mice by BCG Formulated HCV Core Protein Elicited Higher Th1-Oriented Responses Compared to Pluronic-F127 Copolymer. Hepatitis Monthly. 2013; 13(10)[DOI]
  • 31. Baekkevold ES, Yamanaka T, Palframan RT, Carlsen HS, Reinholt FP, von Andrian UH, et al. The CCR7 ligand elc (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment. J Exp Med. 2001; 193(9): 1105-12[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader